DNAPrint Genomics, Inc.: better drugs for segmented markets

Author: Frudakis, Tony

Source: Pharmacogenomics, Volume 9, Number 2, February 2008 , pp. 247-251(5)

Buy & download fulltext article:

Price: $63.00 plus tax (Refund Policy)

Abstract:

The postgenome era promises more efficient drug-development cycles and medications targeted to compatible populations, resulting in improved outcomes, fewer drug-company failures, less litigation, fewer recalls and a refurbished image of ``pharma'' in the mind of the customer. DNAPrint was founded to help precipitate these changes. Since 1999, we have developed and optimized novel methods for assessing patient response proclivities as individuals but also as constituents of populations, and we have introduced a computational platform for modeling drug biology. We expect these tools will allow us to maximize the efficiency of our clinical trials and, more importantly, ensure better postmarket performance parameters. With these tools, we are now carefully engineering select drug-development projects in an attempt to illustrate the viability of a novel drug-development model -- one based on the application of intelligence and new technologies for superior drug performance in segmented markets.

Keywords: ancestry; drug; model; pharmacogenomics; population; SNP

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14622416.9.2.247

Affiliations: 1: DNAPrint Genomics, Inc., 1621 West University Parkway, Sarasota, FL 34243-2732, USA., Email: tonynfrudakis@dnaprint.com

Publication date: 2008-02-01

More about this publication?

Pharmacogenomics provides the community with an essential resource for keeping abreast of the latest developments in new pharmacogenomic initiatives, emerging technologies for accessing genomic information and the development of novel diagnostic products and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites